SS-31 vs Slu Pp 332: A Research Reference
SS-31 and Slu Pp 332 are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Compound profiles
SS-31 in the indexed record
Searching SS-31 against the PubMed index returns 287 records, a moderate evidence base, alongside 2 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Biochem Biophys Res Commun, J Neuroinflammation, Neuromolecular Med, spanning 2019–2025.
- SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease — Oxid Med Cell Longev, 2022. PMID: 35707274
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice — J Neuroinflammation, 2019. PMID: 31747905
- SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function — Organogenesis, 2025. PMID: 40570323
- SS-31 Improves Cognitive Function in Sepsis-Associated Encephalopathy by Inhibiting the Drp1-NLRP3 Inflammasome Activation — Neuromolecular Med, 2023. PMID: 36333543
Slu Pp 332 in the indexed record
Searching Slu Pp 332 against the PubMed index returns 10 records, a limited evidence base with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include ACS Chem Biol, Circulation, Int J Biol Macromol, spanning 2023–2026.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome — J Pharmacol Exp Ther, 2024. PMID: 37739806
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — Circulation, 2024. PMID: 37961903
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential — Rapid Commun Mass Spectrom, 2026. PMID: 41588687
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling — Int J Biol Macromol, 2026. PMID: 41850449
How the literature differs
The indexed record is not symmetrical between these two compounds. SS-31 carries 277 more indexed records than Slu Pp 332, which means published methodology, characterisation data and replication attempts are more readily located for SS-31. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (2 vs 0) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | SS-31 | Slu Pp 332 |
|---|---|---|
| PubMed indexed records | 287 | 10 |
| Registered studies (ClinicalTrials.gov) | 2 | 0 |
| Literature depth | Moderate | Emerging |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
SS-31 and Slu Pp 332 sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for SS-31 describes conditions validated for SS-31: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Slu Pp 332 without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Frequently asked questions
Are SS-31 and Slu Pp 332 the same compound?
No. They are structurally distinct research compounds with separate literature records — 287 indexed records for SS-31 and 10 for Slu Pp 332.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of SS-31 or Slu Pp 332 has more published research?
SS-31, with 287 indexed PubMed records against 10.
Related references
- SS-31 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.